Trials / Completed
CompletedNCT03568409
ABO-GLYC in Type 2 Diabetes
Efficacy of ABO-GLYC on Glycemic and Metabolic Status of Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Aboca Spa Societa' Agricola · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ABO-GLYC | 3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks. |
| OTHER | ABO-GLYC Placebo | 3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks. |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2018-06-26
- Last updated
- 2022-06-30
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03568409. Inclusion in this directory is not an endorsement.